CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 11 enrolled
Drug / intervention
LY2835219 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02327143
NCT02327143Phase 1Completed
CompareCT.gov

An Absolute Bioavailability Study of LY2835219 in Healthy Subjects Using the Intravenous Tracer Method

Eli Lilly and Company·interventional·Posted Dec 30, 2014·Updated Aug 6, 2018

In Brief

A Phase 1 clinical trial evaluating LY2835219 and ¹³C₈-LY2835219 for Healthy Volunteers. Completed, enrolled 11 participants across 1 site.

Detailed Summary

The aim of this study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and as an intravenous infusion (given directly into a vein via a small needle). The study will also provide information on how well the study drug is tolerated when given as a capsule in combination with giving it intravenously, and information on any changes in heart function. The study will last about 10 days. Screening is required within 28 days before study drug is given.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 30, 2014
Enrollment StartJan 1, 2015
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.5 years ago

Interventions

LY2835219drug

Administered orally

¹³C₈-LY2835219drug

Administered IV